Académique Documents
Professionnel Documents
Culture Documents
5 August 2005
Primer
Pharmaceuticals for BeginnersThird Edition The August 2005 publication of 'Pharmaceuticals for Beginners' is the third edition of this industry beginners' guide, which was first published in 2001. Structured in three parts, this comprehensive report includes details on the workings of the industry, key therapeutic markets and a summary of the leading drug companies.
Industry Focus
Global Pharmaceuticals
Pharmaceuticals for Beginners
Heidi Sprang
Research Analyst (44) 20 754 75875 heidi.sprang@db.com
Mark Purcell
Research Analyst (44) 20 754 76522 mark.purcell@db.com
Barbara Ryan
Research Analyst (1) 203 863-2239 barbara.ryan@db.com
Deutsche Bank AG/London All prices are those current at the end of the previous trading session unless otherwise indicated. Deutsche Bank does and seeks to do business with companies covered in its research reports. Thus, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Independent, third-party research (IR) on certain companies covered by DBSI's research is available to customers of DBSI in the United States at no cost. Customers can access this IR at http://equities.research.db.com, or call 1-877-208-6300 to request that a copy of the IR be sent to them. DISCLOSURES AND ANALYST CERTIFICATIONS ARE LOCATED IN APPENDIX 1
Global Pharmaceuticals
5 August 2005
Primer
Mark Purcell
Research Analyst (44) 20 754 76522 mark.purcell@db.com
Barbara Ryan
Research Analyst (1) 203 863-2239 barbara.ryan@db.com
Pharmaceuticals for BeginnersThird Edition The August 2005 publication of 'Pharmaceuticals for Beginners' is the third edition of this industry beginners' guide, which was first published in 2001. Structured in three parts, this comprehensive report includes details on the workings of the industry, key therapeutic markets and a summary of the leading drug companies. So, youve inherited the pharmaceutical sector. Big companies, loads of market cap and interesting diseases with some very silly names. Fantastic finally youve got to follow a stock market industry that might actually be of some interest to that person sitting next to you at a dinner party. But wait. Why do all these drugs have at least two names and how do they work? What is a COX 2 inhibitor and why cant analysts just say heart attack or acid stomach instead of using lengthy terms like myocardial infarction or gastroesophageal reflux disorder? And what on earth is a randomised, placebocontrolled, double blind, intention to treat, Phase III clinical trial anyway? Oh no, what have I done?! In our view, the pharmaceutical industry is fascinating, exciting and of obvious relevance beyond the stock market. But it is also very technical and comprises a minefield of products, names and pathways. Keeping track of it all can, at times, prove bewildering, and not just for the uninitiated. With this in mind, in January 2001, the global pharmaceutical team at Deutsche Bank first published a document that we hoped would prove of use for beginners and industry old hands alike Pharmaceuticals for Beginners. Such a success the first edition was that we are now on our third edition in which we have further updated and expanded our original text. As in the past, the report is structured in three parts providing insight into industry basics, therapeutic markets and the worlds leading pharmaceutical companies. The current edition covers some 25disease areas, including an expanded oncology section as this therapeutic area has been one of the most rapidly evolving in recent years. We have also included a new section on the US litigation process (key for following patent lawsuits) as well as an expanded discussion on Medicare and the new prescription drug benefit. Pharmaceuticals for Beginners is not intended to be read cover to cover, but is meant as an easy-to-use reference guide. Although our concept was to provide beginners with an easy-to-comprehend insight into an undoubtedly complex industry, we hope that it will also continue to find favour among more learned readers as well. Overall, we trust that our readers will find it a valuable and useful document and entrust it with a permanent slot on an already overcrowded desk. So, for those who want to know exactly what a dual PPAR agonist is, turn to the therapeutic comments on diabetes, or to understand why VEGF inhibitors have been gaining so much attention, turn to the oncology section. We wish you a happy and informative read. Deutsche Bank AG/London All prices are those current at the end of the previous trading session unless otherwise indicated. Deutsche Bank does and seeks to do business with companies covered in its research reports. Thus, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Independent, third-party research (IR) on certain companies covered by DBSI's research is available to customers of DBSI in the United States at no cost. Customers can access this IR at http://equities.research.db.com, or call 1-877-208-6300 to request that a copy of the IR be sent to them. DISCLOSURES AND ANALYST CERTIFICATIONS ARE LOCATED IN APPENDIX 1
5 August 2005
Pharmaceuticals Team
Global Pharmaceuticals Heidi Sprang +44 20 7547 5875 heidi.sprang@db.com European Pharmaceuticals Mark Purcell +44 20 7547 6522 mark.purcell@db.com Holger Blum +49 69 910 31912 holger.blum@db.com Alex Evans +44 207 547 1784 alex.evans@db.com Brian White +44 187 5341 442 brian.white@db.com Jan Willard +44 207 547 7013 jan.willard@db.com Yi-Dan Wang +44 207 545 9999 yi-dan.wang@db.com US Pharmaceuticals Barbara Ryan +1 203 863 2239 barbara.ryan@db.com George Drivas +1 203 863 2242 george.drivas@db.com Ross Muken +1 203 863 2245 ross.muken@db.com Research Assistants Emma Gibbs +44 207 545 1547 emma.gibbs@db.com Patricia Eager +1 212 469 5497 patricia.eager@db.com
Table of Contents
Therapeutic Review......................................................................... 99
Diabetes Mellitus...................................................................................................101 Cardiovascular disorders ......................................................................................107 Atherosclerosis................................................................................................107 Hypertension ...................................................................................................109 Dyslipidaemia ..................................................................................................115 Thrombosis and the Antithrombotics...........................................................119 Erectile Dysfunction ..............................................................................................123 Gastrointestinal disorders ....................................................................................127
Page 2
5 August 2005
Respiratory disorders............................................................................................131 Asthma .............................................................................................................131 Chronic Obstructive Pulmonary Disorder ....................................................137 Allergic Rhinitis ...............................................................................................141 Musculoskeletal & inflammatory disorders........................................................147 Osteoporosis....................................................................................................147 Pain ...................................................................................................................153 Rheumatoid Arthritis ......................................................................................159 Transplantation and Immunosuppression ...................................................165 Multiple Sclerosis ...........................................................................................171 Infectious diseases ................................................................................................175 Antibiotics........................................................................................................175 Human Immunodeficiency Virus (HIV) .........................................................183 Viral Hepatitis ..................................................................................................189 Influenza...........................................................................................................193 Central Nervous System Disorders .....................................................................195 Schizophrenia ..................................................................................................197 Parkinsons Disease ........................................................................................203 Alzheimers Disease........................................................................................205 Affective Disorders (Depression)...................................................................209 Attention Deficit Hyperactivity Disorder ......................................................213 Migraine ...........................................................................................................217 Oncology ................................................................................................................221 Colorectal cancer ............................................................................................231 Lung cancer......................................................................................................233 Breast cancer ...................................................................................................235 Prostate cancer................................................................................................237 Anaemia (Erythropoietins) .............................................................................241
Deutsche Bank AG/London Page 3
5 August 2005
Page 4
5 August 2005
Page 5
5 August 2005
Overview
A $500bn industry In 2004, pharmaceutical industry revenues from prescription drugs totalled over $500bn. From a value of nearer $70bn in 1981, the industry has recorded compound annual revenue growth of just under 10% and, despite todays much greater size, it is of note that underlying volume growth rates have seen little sign of abatement over the 20-year period. Geographically, the US has grown in importance and today accounts for roughly 50% of total industry sales. US revenues have gained not only from a more favourable pricing environment but also from the growth of biotech-derived products and the market stimulus provided by direct-to-consumer advertising. Freedom of choice in US healthcare markets, combined with market-based pricing, argue that US growth will continue to outpace that of the other major world markets and that the US will continue to increase in importance overall. By contrast, government-influenced buying and formulary control have meant that the importance of European revenues as a percentage of the total industry has declined over the past 20 years. Today, Europe accounts for less than 30% of global revenues. Equally, the Japanese governments influence in domestic pharmaceutical markets has restricted the rate of absolute sales growth, with Japanese end-markets today accounting for 11% of total industry sales. Figure 1: Value of the pharmaceutical industry 1981-2004 ($ bn)
600
500 400
300
200
100 0 1981
Source: IMS Health, Deutsche Bank estimates
1986
1990
1995
2000
2002
2004
Page 6
5 August 2005
Cardiovascular and CNS drugs dominate By therapeutic category, todays industry is dominated by demand for cardiovascular drugs (including the cholesterol-lowering agents), which, in 2004, were estimated to account for nearly 20% of industry sales, or around $90bn by value. Pharmaceuticals for disorders of the central nervous system an area that remains poorly understood in medical terms represent the second-largest category, driven in recent years by the emergence of important drugs for treating mental illnesses such as depression and schizophrenia. Anti-infectives, predominantly antibiotics, retain their importance as a major therapeutic class, despite the age of many of the key products. In 2004, we estimate that anti-infectives represented 8% of global pharmaceutical sales. Elsewhere, strong growth in genito-urinary treatments, most significantly those for ulcers and acid reflux, has enabled them to retain a 5% share of global markets, while the growing prevalence of respiratory diseases such as asthma in the industrialised world, has seen this category retain its 9% share. Figure 2: 2004 drug sales by region
RoW 8%
Oncology 5% GI 5% Musculoskeletal 7%
North America 49%
Europe 28%
Respiratory 9%
Consolidating, but still fragmented From a company perspective, innovation and consolidation have meant that an increasing proportion of global sales are concentrated in the hands of the top ten players. This process has accelerated in recent years, following the mega-mergers of companies like Glaxo Wellcome with SmithKline Beecham and Sanofi-Synthelabo with Aventis (where all four of the legacy companies were themselves created by mergers within the past ten years), Pfizer with Warner-Lambert and, shortly afterwards, Pfizer with Pharmacia. The ongoing process of focus by the worlds chemical industries has also seen companies such as DuPont and BASF reconsider their ambitions in what were historically core markets, BASF selling its Knoll business to Abbott and DuPont its pharmaceutical assets to Bristol-Myers. We estimate that the top ten ethical pharmaceutical companies accounted for around 55% of industry revenues in 2004, against 25% two decades earlier. However, despite this consolidation, it is of significance that the worlds largest company, Pfizer, still accounts for only 11% of industry revenues. In part, this pays testament to the sustained innovation evident in the industry and the fact that, despite its absolute scale, markets are not mature and growth comfortably in excess of world GDP is still, in our view, achievable.
Page 7
5 August 2005
Individual drugs, too, have become larger, with the top ten today accounting for around 10% of total industry revenues, against just 5% two decades ago. In 2004, 82 drugs achieved $1bn blockbuster status, with the worlds largest drug, the cholesterol-lowering Lipitor, realising sales in excess of $10bn. Figure 4: The market shares of the top ten companies 1981-2005E
60%
50%
40%
30% . 20%
10%
0% 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005E
Page 8
5 August 2005